February 14, 2022
Life Sciences
  • The Federal Trade Commission will vote Thursday on whether it will study how pharmacy benefit managers (PBMs) affect drug prices and the businesses of pharmacies. The vote comes after years of pharmacies’ complaints over PBM fees for reimbursement, quality metrics, and more. The FTC is expected to target the “competitive impact of contractual provisions and reimbursement adjustments,” including fees PBMs claw back from pharmacies. (Articles here and here)